We’re thrilled to announce the launch of our a new audio-only, short form podcast that dives into the world of healthcare and pharmacy! RxSNIPS is a perfect bite-sized supplement to the video podcast interviews.
https://t.co/FMqh76M7Yr
We’re thrilled to announce the launch of our a new audio-only, short form podcast that dives into the world of healthcare and pharmacy! RxSNIPS is a perfect bite-sized supplement to the video podcast interviews.
https://t.co/FMqh76M7Yr
Season 1 is BACK! New episodes now streaming on YouTube and Spotify!
https://t.co/D7vjazZVED
https://t.co/9ylFPOCOnd
#pharmacy#podcast#healthcarepodcast
The full scope of pharmacy practice offers a transformative approach to health care delivery, promising improved patient outcomes, greater access to care, and efficient utilization of health care resources.
Read More: https://t.co/pAeFAL4cOe
EXCITING NEWS!
It is official. Season 1, Part 2 episodes of the Podcast will be dropping next week on Wednesday February 28th on both YouTube and Spotify! Can't wait to share some amazing interviews on critical topics with highly insightful guests.
Stay tuned for more!
Tune in to this episode of Pharmacy Focus for a deep dive into the world of independent pharmacists prescribing, featuring insights and expertise from Deeb Eid.
Listen Here: https://t.co/hvart6VRxj
3) Large-scale implementation in the U.S. could lead to substantial national health and economic benefits.
4) The model predicts a reduction in healthcare costs, with savings of $10,162 per person over 30 years.
Big News in Healthcare! Just summarized a study revealing how pharmacist-prescribing can transform hypertension care. It's about saving lives, reducing diseases, and slashing costs. But there's more to it...
Check out the key insights and surprises in the thread below.
Top 5 Key Takeaways:
1) Pharmacist-prescribing interventions can significantly improve HTN control and reduce cardiovascular and kidney diseases.
2) These interventions offer cost savings and additional quality-adjusted life years (QALYs) for patients.
The intervention showed reduced cases of cardiovascular disease and kidney disease, improved life years and QALYs, and cost savings per person. At the population level, the intervention could result in significant cost savings and improved health outcomes.
It employs a 5-state Markov model, based on a previous Alberta Clinical Trial, and analyzes data for cost-effectiveness, cardiovascular events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER).
The study, titled "Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States," evaluates the economic viability and health outcomes of a pharmacist-prescribing intervention for hypertension (HTN) control in the U.S.